UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Diabetes, obesity & metabolism, 2014-04, Vol.16 (4), p.366-375

2014

Volltextzugriff (PDF)

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

Diabetic medicine, 2016-04, Vol.33 (4), p.471-477

2016

Volltextzugriff (PDF)

What is innovation in the area of medicines? The example of insulin and diabetes

Diabetic medicine, 2019-12, Vol.36 (12), p.1528-1529

2019

Volltextzugriff (PDF)

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Journal of medical economics, 2015-01, Vol.18 (1), p.56-68

2015

Volltextzugriff (PDF)

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Diabetic medicine, 2015-08, Vol.32 (8), p.1023-1035

2015

Volltextzugriff (PDF)

Evaluating the long-term cost-effectiveness of introducing a smart insulin pen in standard-of-care treatment of type 1 diabetes in Sweden

Diabetologia, 2020, Vol.63 (Suppl. 1), p.S381

2020

Volltextzugriff (PDF)

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

Alzheimer's research & therapy, 2024-02, Vol.16 (1), p.48-11, Article 48

2024

Volltextzugriff (PDF)

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Current medical research and opinion, 2017-04, Vol.33 (4), p.647-655

2017

Volltextzugriff (PDF)

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

Scandinavian journal of public health, 2006-10, Vol.34 (5), p.462-471

GUNDGAARD, JENS

2006

Volltextzugriff (PDF)

Income related inequality in prescription drugs in Denmark

Pharmacoepidemiology and drug safety, 2005-05, Vol.14 (5), p.307-317

Gundgaard, Jens

2005

Volltextzugriff (PDF)

Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records

Journal of clinical pharmacy and therapeutics, 2005-06, Vol.30 (3), p.259-269

2005

Volltextzugriff (PDF)

The effect of non-response on estimates of health care utilisation: linking health surveys and registers

European journal of public health, 2008-04, Vol.18 (2), p.189-194

2008

Volltextzugriff (PDF)

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

Patient preference and adherence, 2013-01, Vol.7 (default), p.925-936

2013

Volltextzugriff (PDF)

Increased intake of fruit and vegetables: estimation of impact in terms of life expectancy and healthcare costs

Public health nutrition, 2003-02, Vol.6 (1), p.25-30

2003

Volltextzugriff (PDF)

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes in a Swedish setting

DIABETOLOGIA, 2019, Vol.62, p.S436

2019

Volltextzugriff (PDF)

Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease

International journal of technology assessment in health care, 2005-04, Vol.21 (2), p.194-202

2005

Volltextzugriff (PDF)

The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark

Ugeskrift for læger, 2005-05, Vol.167 (21), p.2273

2005

Volltextzugriff (PDF)

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

Diabetes therapy, 2021-01, Vol.12 (1), p.373-388

2021

Volltextzugriff (PDF)

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial

Advances in therapy, 2020-05, Vol.37 (5), p.2413-2426

2020

Volltextzugriff (PDF)

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

Diabetes therapy, 2018-06, Vol.9 (3), p.1217-1232

2018

Volltextzugriff (PDF)

The Danish Testicular Cancer database

Clinical epidemiology, 2016-01, Vol.8, p.703-707

2016

Volltextzugriff (PDF)

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Journal of medical economics, 2020-11, Vol.23 (11), p.1311-1320

2020

Volltextzugriff (PDF)

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Applied health economics and health policy, 2019-10, Vol.17 (5), p.615-627

2019

Volltextzugriff (PDF)

Third-line therapy for metastatic colorectal cancer

Cancer chemotherapy and pharmacology, 2008-01, Vol.61 (1), p.1-13

2008

Volltextzugriff (PDF)

1 – 24 von 24

Suche als RSS-Feed

Aktive Filter

KollektionElsevier ScienceDirect Journals Complete

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)

Publikationsform

Artikel
(23)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(20)
Science & Technology
(20)
Humans
(16)
Diabetes
(10)
Adult
(9)
Female
(9)
Male
(8)
Cost-Benefit Analysis
(7)
Hypoglycemia
(7)
Hypoglycemic Agents - Economics
(6)
Insulin
(6)
Middle Aged
(6)
Public, Environmental & Occupational Health
(6)
Cost-Effectiveness
(5)
Endocrinology & Metabolism
(5)
Hypoglycemic Agents - Therapeutic Use
(5)
Insulin, Long-Acting - Economics
(5)
Medicin Och Hälsovetenskap
(5)
Medicine
(5)
Medicine & Public Health
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness of insulin degludec compared with insulin glargine for patients with type 2 diabetes treated with basal insulin - from the UK health care cost perspective

Severe hypoglycaemia in adults with insulin-treated diabetes: impact on healthcare resources

What is innovation in the area of medicines? The example of insulin and diabetes

Cost-effectiveness of insulin degludec compared with insulin glargine in a basal-bolus regimen in patients with type 1 diabetes mellitus in the UK

Development and validation of a cost-utility model for Type 1 diabetes mellitus

Evaluating the long-term cost-effectiveness of introducing a smart insulin pen in standard-of-care treatment of type 1 diabetes in Sweden

Progression analysis versus traditional methods to quantify slowing of disease progression in Alzheimer's disease

Cost-effectiveness of switching to insulin degludec from other basal insulins: evidence from Swedish real-world data

Income-related inequality in utilization of health services in Denmark: Evidence from Funen County

Income related inequality in prescription drugs in Denmark

Use of six main drug therapeutic groups across educational groups: self-reported survey and prescription records

The effect of non-response on estimates of health care utilisation: linking health surveys and registers

Descriptions of health states associated with increasing severity and frequency of hypoglycemia: a patient-level perspective

Increased intake of fruit and vegetables: estimation of impact in terms of life expectancy and healthcare costs

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes in a Swedish setting

Cost-effectiveness of nutritional counseling for obese patients and patients at risk of ischemic heart disease

The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark

Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis

Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial

DEVOTE 5: Evaluating the Short-Term Cost-Utility of Insulin Degludec Versus Insulin Glargine U100 in Basal–Bolus Regimens for Type 2 Diabetes in the UK

The Danish Testicular Cancer database

Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective

Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16)

Third-line therapy for metastatic colorectal cancer

Aktive Filter

Suchergebnisse filtern